QSAR investigation of NaV1.7 active compounds using the SVM/Signature approach and the Bioclipse Modeling platform

Ulf Norinder1, Maria E Ek

  • 1AstraZeneca Research and Development Södertälje, SE-151 85 Södertälje, Sweden. ulfn@lundbeck.com